Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts.

Abstract:

:The efficacy of All-Trans Retinoic Acid (Atra) and Arsenic Trioxide (As(2)O(3)) in the treatment of Acute Promyelocytic Leukemia (APL) is well known. Further, these drugs inhibit cell growth and induce apoptosis in several cell lines, but few data are reported on leukemic blasts. The aim of this study was to evaluate the biological effects on non-M3 Acute Myeloid Leukemia (AML) cells. Blasts of six patients, after exposition to Atra and As(2)O(3) were tested for growth inhibition, induction of apoptosis and change in cell cycle distribution, evaluating cell viability, percentage of apoptotic cells and of blasts positive for Ki-67 and BrdU. In the present study we demonstrated that either Atra or As(2)O(3) inhibit leukemic cells proliferation by induction of apoptosis. The effects are time and dose dependent. We did not observe additive or synergistic effects with the combination of the drugs. Further, our results showed that Atra and As(2)O(3) have effects on cell cycle distribution reducing S-phase and proliferating cells. These results should be taken in to account preparing future laboratory and clinical experimental protocols that associate these drugs with antineoplastic agents with different cell cycle specificity.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Cosenza M,Civallero M,Sacchi S,Marcheselli R,Pozzi S

doi

10.1080/10428190400014991

keywords:

subject

Has Abstract

pub_date

2005-02-01 00:00:00

pages

257-63

issue

2

eissn

1042-8194

issn

1029-2403

pii

QLPCXKUBRPV3555X

journal_volume

46

pub_type

杂志文章
  • Expression of the IL2 receptor alpha, beta and gamma chains in hairy cell leukemia.

    abstract::The expression of the interleukin 2 (IL2) receptor chains was investigated by immunofluorescence and mRNA analysis in typical and variant hairy cell leukemia (HCL) cases. While typical hairy cells express both the alpha and the beta chains, variant HCL express the IL2 receptor beta chain on the surface membrane but no...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:

    authors: de Totero D,Carbone A,Tazzari PL,Raspadori D,Ventura A,Reato G,Lauria F,Foa R

    更新日期:1994-01-01 00:00:00

  • Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.

    abstract::Recent clinical data suggest remarkable activity of ibrutinib, the first-in-class covalent inhibitor of Bruton's tyrosine kinase (BTK), in chronic lymphocytic leukemia (CLL), as well as excellent activity in other B cell malignancies, including in particular mantle cell lymphoma and Waldenstrom macroglobulinemia. This...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2013.803226

    authors: Brown JR

    更新日期:2014-02-01 00:00:00

  • All-trans retinoic acid (ATRA) and the regulation of adhesion molecules in acute myeloid leukemia.

    abstract::A review of recent information on the expression and the ATRA-driven modulation of cell surface adhesion molecules of acute myelogenous leukemia blast cells is presented. Cytofluorometric studies on fresh blast cells have demonstrated that CD11a, CD11b CD11c, CD15, CD45RO and CD54 expression is significantly lower in ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199209067601

    authors: Di Noto R,Lo Pardo C,Schiavone EM,Ferrara F,Manzo C,Vacca C,Del Vecchio L

    更新日期:1996-04-01 00:00:00

  • Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia.

    abstract::Relapse represents the main cause of treatment failure after allogeneic stem cell transplant (allo-SCT). The detection of minimal residual disease (MRD) by multiparametric flow cytometry (MFC), chimerism, cytogenetics and molecular analysis may be critical to prevent relapse. Therefore, we assessed the overall agreeme...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.789508

    authors: Rossi G,Carella AM,Minervini MM,Savino L,Fontana A,Pellegrini F,Greco MM,Merla E,Quarta G,Loseto G,Capalbo S,Palumbo G,Cascavilla N

    更新日期:2013-12-01 00:00:00

  • Down regulation of stem cell colony formation by purified CD8 lymphocytes and CD8 conditioned medium: potential importance for bone marrow transplantation in leukemia.

    abstract::A methodology for selection of the CD8 cell subset from the peripheral blood and bone marrow mononuclear cells was developed using anti-T8 (CD8) antibody and magnetic microspheres coated with anti-mouse IgG. Following optimization of antibody:cell binding ratio and microsphere:cell ratios, CD8(+)-cells in the peripher...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199209049825

    authors: Gazitt Y,He YJ

    更新日期:1992-09-01 00:00:00

  • Therapy-related acute lymphoblastic leukemia with MLL rearrangement following treatment of Burkitt's leukemia.

    abstract::The occurrence of therapy-related acute lymphoblastic leukemia (ALL) is rare and, to our knowledge, is not reported in patients treated for Burkitt's leukemia. We report on a child with ALL with translocation t(4;11)(q21;q23) involving the MLL gene, 13 months after chemotherapy for Burkitt's leukemia. This present obs...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500052248

    authors: Millot F,Brizard F,Sorel N,Preudhomme C,Cividin M,Guilhot F,Brizard A

    更新日期:2005-06-01 00:00:00

  • Are alkylating agents a necessary component in the therapy of Hodgkin's disease.

    abstract::Management of early stages of Hodgkin's disease requires development of treatment programs that are nominally toxic, with a low likelihood of sterility and secondary malignancies, both associated with alkylating agents. Although patients with laparotomy-staged disease without B symptoms or large mediastinal masses hav...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199309149119

    authors: Hagemeister FB

    更新日期:1993-01-01 00:00:00

  • Clinical outcome of chronic myeloid leukemia imatinib-resistant patients: do BCR-ABL kinase domain mutations affect patient survival? First multicenter Argentinean study.

    abstract::In imatinib-treated patients with chronic myeloid leukemia (CML), BCR-ABL mutations are the most common mechanism of resistance. Here we report the first multicenter Argentinean study investigating mutations in those patients with CML who fail or lose response to imatinib, with or without previous interferon treatment...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.3109/10428194.2011.578310

    authors: Bengió RM,Riva ME,Moiraghi B,Lanari E,Milone J,Ventriglia V,Bullorsky E,Tezanos Pinto Md,Murro H,Bianchini M,Larripa I

    更新日期:2011-09-01 00:00:00

  • Biosimilars of filgrastim in autologous stem cell transplant: reduction in granulocyte-colony stimulating factor costs, but similar effects on bone marrow recovery.

    abstract::Granulocyte-colony stimulating factors (G-CSFs) enhance bone marrow (BM) recovery after autologous stem cell transplant (ASCT) in patients with lymphoma and myeloma. Few publications exist that discuss the use of filgrastim biosimilars after ASCT. We conducted a single-center retrospective study in patients with lymph...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.791984

    authors: Ianotto JC,Ngo Sack F,Couturier MA,Tempescul A,Mugnier N,Delepine P,Guillerm G,Berthou C

    更新日期:2014-01-01 00:00:00

  • Intratumoral plasmacytoid dendritic cells associate with increased survival in patients with follicular lymphoma.

    abstract::Gene array studies on follicular lymphoma (FL) have associated non-malignant tumor-infiltrating immune cells with patient survival. We examined the role of such cells detectable by immunohistochemistry in a tissue microarray, focusing on plasmacytoid dendritic cells (pDCs). These cells physiologically produce interfer...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.569619

    authors: Butsch R,Lukas Waelti S,Schaerer S,Braun J,Korol D,Probst-Hensch N,Moch H,Kurrer M

    更新日期:2011-07-01 00:00:00

  • Serum interleukin-6 levels in patients with thrombocytosis.

    abstract::Interleukin-6 (IL-6) has been shown to increase platelet counts in several animal models and to enhance megakaryocytopoiesis in vitro. In order to investigate the possible relationship between IL-6 and thrombocytosis, serum IL-6 levels in patients with platelet counts > or = 6 x 10(5)/microliters were measured using a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199209054910

    authors: Hollen CW,Henthorn J,Koziol JA,Burstein SA

    更新日期:1992-10-01 00:00:00

  • Bone marrow scintigraphy as a useful method for estimating the physiological status of bone marrow and spleen in polycythaemia vera.

    abstract::Bone marrow scintigraphy is a simple and noninvasive examination useful to define the status of the bone marrow and spleen in polycythaemia vera (P.V.). Despite the absence of specificity of Indium 111 labelled transferrin (In-Tf) for myelopoietic tissue, there is a close correlation between bone marrow In-Tf uptake a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199609074367

    authors: Rain JD,Najean Y,Billotey C

    更新日期:1996-09-01 00:00:00

  • Clinical and epidemiological features of acute lymphoblastic leukemia following a previous malignancy.

    abstract::Secondary malignancies represent a relevant complication of chemotherapy employed for a previous cancer. Acute leukemias represent the most frequent secondary malignancy in the first decade following primary neoplasms; secondary leukemias are generally myeloid and can be preceeded by a myelodysplastic syndrome. The bi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190009113377

    authors: Pagano L,Pulsoni A,Mele L,Leone G

    更新日期:2000-11-01 00:00:00

  • Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemic HL-60 cells.

    abstract::The induction of apoptosis following topoisomerase inhibitors proceeds in at least three distinct steps: (1) induction of cleavable complexes (potentially lethal damage), (2) topoisomerase-induced DNA damage, and (3) a presently unknown sequence of events that must either lead to cell cycle arrest (G2-block, different...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199409051674

    authors: Solary E,Bertrand R,Pommier Y

    更新日期:1994-09-01 00:00:00

  • Alterations of P53 and RB genes and the evolution of the accelerated phase of chronic myeloid leukemia.

    abstract::Using the single-strand conformation polymorphism and heteroduplex analyses, the P53 and RB genes were analyzed in cell samples from twenty-eight patients with chronic myeloid leukemia (CML) both at diagnosis and at the onset of accelerated phase (AP) of the disease. No alterations of the P53 or RB genes were found in...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190009059278

    authors: Beck Z,Kiss A,Tóth FD,Szabó J,Bácsi A,Balogh E,Borbély A,Telek B,Kovács E,Oláh E,Rak K

    更新日期:2000-08-01 00:00:00

  • Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells.

    abstract::The tyrosine kinase inhibitors (TKIs), nilotinib, ponatinib, and dasatinib (but not bosutinib or imatinib), are associated with vascular adverse events (VAEs) in chronic myeloid leukemia (CML). Though the mechanism is inadequately understood, an effect on vascular cells has been suggested. We investigated the effect o...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1466294

    authors: Gover-Proaktor A,Granot G,Pasmanik-Chor M,Pasvolsky O,Shapira S,Raz O,Raanani P,Leader A

    更新日期:2019-01-01 00:00:00

  • Epstein-Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1.

    abstract::Rituximab is a CD20-targeted monoclonal antibody widely used in the treatment of B-cell lymphoma. Previously, we have shown that Epstein-Barr virus (EBV) latent membrane protein-1 (LMP1) increases chemoresistance in malignant cancer cells. In this study we examined the effects of LMP1 on the response of B-cell lymphom...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.659736

    authors: Kim JH,Kim WS,Park C

    更新日期:2012-08-01 00:00:00

  • Pneumocystis jiroveci pneumonia in relation to CD4+ lymphocyte count in patients with B-cell non-Hodgkin lymphoma treated with chemotherapy.

    abstract::An increasing incidence of Pneumocystis jiroveci pneumonia (PCP) in patients with B-cell non-Hodgkin lymphoma (B-NHL) receiving rituximab treatment has been reported. We reviewed patients with B-NHL who underwent chemotherapy from 2004 to 2008 at our institution to identify risk factors for PCP development during and ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2010.506569

    authors: Hashimoto K,Kobayashi Y,Asakura Y,Mori M,Azuma T,Maruyama D,Kim SW,Watanabe T,Tobinai K

    更新日期:2010-10-01 00:00:00

  • Why do B cell lymphoma fail to elicit clinically sufficient T cell immune responses?

    abstract::There is no doubt that human B cell lymphoma does not elicit a clinically sufficient T cell mediated immune response that results in tumor rejection. However, the mechanisms leading to this lack of T cell recognition and effector function are still not fully understood. Many potential mechanisms such as "ignorance" in...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199909167383

    authors: Schultze JL

    更新日期:1999-01-01 00:00:00

  • Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma.

    abstract::This phase-I/phase-II study evaluated panobinostat in combination with ifosfamide, carboplatin, etoposide (P-ICE) in relapsed/refractory classical Hodgkin lymphoma. During phase I, panobinostat was given daily on Monday/Wednesday/Friday starting one week prior to Cycle 1 (C1) of ICE and during two weeks of C1-2 of ICE...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,随机对照试验

    doi:10.1080/10428194.2017.1359741

    authors: Hu B,Younes A,Westin JR,Turturro F,Claret L,Feng L,Fowler N,Neelapu S,Romaguera J,Hagemeister FB,Rodriguez MA,Samaniego F,Fayad LE,Copeland AR,Nastoupil LJ,Nieto Y,Fanale MA,Oki Y

    更新日期:2018-04-01 00:00:00

  • Case 30: hypereosinophilia.

    abstract::A young man presented with systemic symptoms and marked eosinophilia. Subsequently cyclical weight gain and edema contributed to a diagnosis. ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190600724878

    authors: Marks AJ,Abdalla SH,Cross NC,Bain BJ

    更新日期:2006-08-01 00:00:00

  • Chromosomal analysis of purified B-chronic lymphocytic leukemia lymphocyte cultures: comparison with whole blood cultures and in situ hybridization.

    abstract::Chromosomal analysis of stimulated whole blood cells and purified B lymphocytes was performed in 13 stage A(0) and 1 stage C(IV) chronic lymphocytic leukemia (B-CLL) patients. Abnormal clones were found in 6 cases in purified B lymphocytes cultures and in a single one in whole blood cultures. In situ hybridization wit...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199309067929

    authors: Brizard A,Brizard F,Dreyfus B,Morel F,Lecron JC,Tanzer J,Preud'Homme JL

    更新日期:1993-11-01 00:00:00

  • Lymphomatous proptosis as a novel feature of mantle cell lymphoma.

    abstract::We describe eight cases of acute proptosis due to mantle cell lymphoma (MCL), among 26 consecutive MCL cases. The median time of onset was 29 months (range 0-102) from diagnosis. Two cases presented initially with orbital masses while five as sudden disease progression after multiple courses of chemotherapy. In each c...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500301058

    authors: Hon C,Chan RT,Ma ES,Shek TW,Yau K,Au WY

    更新日期:2006-01-01 00:00:00

  • The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft-versus-host disease.

    abstract::We have recently shown that the lysosomotropic amine, chloroquine, can inhibit the development of graft-versus-host disease (GVHD) secondary to minor histocompatibility (MiHC) differences in mice. In addition, we have shown that both chloroquine and hydroxychloroquine can inhibit T cell responses in vitro to minor and...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199709039008

    authors: Schultz KR,Gilman AL

    更新日期:1997-01-01 00:00:00

  • Familial erythroleukemia: a distinct clinical and genetic type of familial leukemias.

    abstract::A family with erythroleukemia is presented, in which father and son were diagnosed at the same age, but 20 years apart, with almost identical clinical and morphological features of the disease. No environmental factors were identified. The karyotypic abnormalities of the bone marrow blasts in the son demonstrated 2 ma...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199809057551

    authors: Novik Y,Marino P,Makower DF,Wiernik PH

    更新日期:1998-07-01 00:00:00

  • Molecular pathogenesis of mucosal-associated lymphoid tissue (MALT) lymphoma.

    abstract::Extranodal marginal zone B-cell lymphomas of mucosal-associated lymphoid tissue (MALT)-type occur in a number of anatomic sites, but share overlapping morphological and immunophenotypic features. Helicobacter pylori infection has been identified as an etiological factor in gastric MALT lymphoma, but the cause of MALT ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190310001623793

    authors: Gascoyne RD

    更新日期:2003-01-01 00:00:00

  • Childhood acute lymphoblastic leukemia: is there a tumor suppressor gene in chromosome 12p12.3?

    abstract::Cytogenetic deletions on the short arm of chromosome 12 are common, recurring alterations found in a wide range of hematological neoplasias, including childhood acute lymphoblastic leukemia (ALL), the most frequent pediatric malignancy. This loss of genetic material suggests the presence of a tumor suppressor gene pla...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199909050948

    authors: Aïssani B,Bonan C,Baccichet A,Sinnett D

    更新日期:1999-07-01 00:00:00

  • Adhesion properties of adult T cell leukemia cells.

    abstract::The interaction between neoplastic as well as normal T cells and vascular endothelial cells which is mediated by adhesion molecules play a key role in their trafficking, localization and infiltration. This brief article reviews our studies on the expression of adhesion molecules on leukemic cells isolated from patient...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199509054426

    authors: Uchiyama T,Ishikawa T,Imura A

    更新日期:1995-02-01 00:00:00

  • Genomic stratification of multiple myeloma treated with novel agents.

    abstract::Cytogenetic testing is now routinely performed for the prognostic work-up of multiple myeloma (MM). The abnormalities del(17p), t(4;14) and del(13q) have been established as predictors of poor outcome in patients with MM treated with conventional chemotherapy or stem cell transplant; chromosome 1q gains and 1p losses ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2011.608449

    authors: Jiang A,Reece D,Chang H

    更新日期:2012-02-01 00:00:00

  • [18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice.

    abstract::Positron emission tomography (PET) after induction therapy in follicular lymphoma (FL) is predictive of survival in clinical trials. We describe use of PET and computed tomography (CT) after rituximab-based induction therapy in FL patients followed by the National LymphoCare Study and explore the association between i...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1213824

    authors: Wong-Sefidan I,Byrtek M,Zhou X,Friedberg JW,Flowers CR,Zelenetz AD,Dawson KL,Reid E

    更新日期:2017-04-01 00:00:00